TOKYO, Dec 20, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa
SK Biopharmaceuticals will unveil its wearable healthcare devices at the upcoming Consumer Electronics Show (CES) next month as part of its plan to advance into the digital healthcare business, its head of R&D said Wednesday. “The bio industry is changing by converging with ICT. We believe there will be a patient-centric period in the bio industry and we will try to lead the trend with our digital healthcare technology,” Hwang Sun-gwan, vice president of SK Biopharmaceuticals R&D Innovation, said during a press conference in Seoul.
The dynamics of developmental and epileptic encephalopathy (DEE) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness
reporter: ebony was 12 the last time she saw her mom, myrtle brown. she was going to new york to get away. reporter: myrtle s brother robert was living in california. they had always been close i had a message on my answering machine all she wade is i m trying to get a hold of you. reporter: that s it yeah, back in those days she didn t have a cellphone, so i was not able to call her. she had called my grandmother to let her know someone stole her purse, her money and it included medication because she was epileptic. sh so she talked about going to the hospital so she could get a refill then that was the last moment, you know, we ever heard from her. reporter: the family checked the hospitals, called the police, but nothing. weeks and months with no answers turned into years and decades. it was very hard. you know, when you have your prom and just, you know, becoming a young woman, it s hard. reporter: she wasn t there for it? no. reporter: and you thought tha